Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT INDUSTRY
2.1 Summary about Chemotherapy Induced Peripheral Neuropathy Treatment Industry
2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
2.2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Production & Consumption Trends
2.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Demand Structure Trends
2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 APX-3330
4.2.2 BR-297
4.2.3 Cannabidiol
4.2.4 Dimiracetam
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Clinic
4.3.2 Hospital
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 APX-3330
5.2.2 BR-297
5.2.3 Cannabidiol
5.2.4 Dimiracetam
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Clinic
5.3.2 Hospital
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 APX-3330
6.2.2 BR-297
6.2.3 Cannabidiol
6.2.4 Dimiracetam
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Clinic
6.3.2 Hospital
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 APX-3330
7.2.2 BR-297
7.2.3 Cannabidiol
7.2.4 Dimiracetam
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Clinic
7.3.2 Hospital
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 APX-3330
8.2.2 BR-297
8.2.3 Cannabidiol
8.2.4 Dimiracetam
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Clinic
8.3.2 Hospital
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 APX-3330
9.2.2 BR-297
9.2.3 Cannabidiol
9.2.4 Dimiracetam
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Clinic
9.3.2 Hospital
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Achelios Therapeutics Inc
10.1.2 Advinus Therapeutics Ltd
10.1.3 Apollo Endosurgery Inc
10.1.4 Aptinyx Inc
10.1.5 Asahi Kasei Pharma Corp
10.1.6 Can-Fite BioPharma Ltd
10.1.7 Celgene Corp
10.1.8 DermaXon LLC
10.1.9 Eisai
10.1.10 Immune Pharmaceuticals Inc
10.1.11 INSYS Therapeutics Inc
10.1.12 Kineta Inc
10.1.13 KPI Therapeutics Inc
10.1.14 Krenitsky Pharmaceuticals Inc
10.1.15 MAKScientific LLC
10.1.16 Metys Pharmaceuticals AG
10.1.17 Midatech Pharma US Inc
10.1.18 Mundipharma International Ltd
10.1.19 Nemus Bioscience Inc
10.1.20 Neurocentrx Pharma Ltd
10.1.21 Panacea Pharmaceuticals Inc
10.1.22 PeriphaGen Inc
10.1.23 PharmatrophiX Inc
10.1.24 PledPharma AB
10.1.25 Sova Pharmaceuticals Inc
10.1.26 Virobay Inc
10.1.27 WEX Pharmaceuticals Inc
10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Date of Major Players (2017-2020e)
10.2.1 Achelios Therapeutics Inc
10.2.2 Advinus Therapeutics Ltd
10.2.3 Apollo Endosurgery Inc
10.2.4 Aptinyx Inc
10.2.5 Asahi Kasei Pharma Corp
10.2.6 Can-Fite BioPharma Ltd
10.2.7 Celgene Corp
10.2.8 DermaXon LLC
10.2.9 Eisai
10.2.10 Immune Pharmaceuticals Inc
10.2.11 INSYS Therapeutics Inc
10.2.12 Kineta Inc
10.2.13 KPI Therapeutics Inc
10.2.14 Krenitsky Pharmaceuticals Inc
10.2.15 MAKScientific LLC
10.2.16 Metys Pharmaceuticals AG
10.2.17 Midatech Pharma US Inc
10.2.18 Mundipharma International Ltd
10.2.19 Nemus Bioscience Inc
10.2.20 Neurocentrx Pharma Ltd
10.2.21 Panacea Pharmaceuticals Inc
10.2.22 PeriphaGen Inc
10.2.23 PharmatrophiX Inc
10.2.24 PledPharma AB
10.2.25 Sova Pharmaceuticals Inc
10.2.26 Virobay Inc
10.2.27 WEX Pharmaceuticals Inc
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
